Tevimbra (tislelizumab-jsgr) — Medica
Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma with Transformation to Diffuse Large B-cell Lymphoma
Initial criteria
- age ≥ 18 years
- histologic transformation to diffuse large B-cell lymphoma
- ONE of the following: tumor has del(17p)/TP53 mutation OR disease is chemotherapy refractory OR patient unable to receive chemoimmunotherapy
- used in combination with Brukinsa (zanubrutinib)
- prescribed by or in consultation with an oncologist
Approval duration
1 year